Mannose receptor contributes to preferential oligomannosidic glycoform clearance in a murine pharmacokinetics model

David Falck(Leiden University Medical Center), Dietmar Reusch(Roche Pharma AG (Germany)), Steinar Gijze(Leiden University Medical Center), Anna Wasynczuk(Leiden University Medical Center), Manfred Wuhrer(Leiden University Medical Center), Martin Lechmann(Roche (Switzerland)), Aline Tridon(Université Fédérale de Toulouse Midi-Pyrénées), Sebastian Malik(Roche Pharma AG (Germany))
mAbs
March 30, 2026
10.1080/19420862.2026.2652119
Cited by 0

Related Papers

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection
|Proceedings of the National Academy of Sciences|2003|170
Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases
|Gastroenterology|2018|164
T– and B–Cell Responses to Different Hepatitis C Virus Antigens in Patients With Chronic Hepatitis C Infection and in Healthy Anti– Hepatitis C Virus—Positive Blood Donors Without Viremi
|Hepatology|1996|149
Immunopurification and Mass Spectrometric Quantification of the Active Form of a Chimeric Therapeutic Antibody in Human Serum
|Analytical Chemistry|2008|144
Vaccination trial with HPV16 L1E7 chimeric virus‐like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3)
|International Journal of Cancer|2007|136